Current clinical trials of NLRP3-targeting kinase inhibitors primarily focus on tumors (such as mantle cell lymphoma) and autoimmune diseases (such as rheumatoid arthritis), and whether NLRP3 phosphorylation is a practical treatment target needs further study (Gong et al., 2018). The gene discussed is NLRP3; the disease is mantle cell lymphoma.